Capricor Therapeutics, Inc. (CAPR) |
4.425 0.025 (0.57%)
|
03-22 12:51 |
Open: |
4.5 |
Pre. Close: |
4.4 |
High:
|
4.5 |
Low:
|
4.35 |
Volume:
|
20,215 |
Market Cap:
|
112(M) |
|
|
Technical analysis |
as of: 2023-03-22 12:15:17 PM |
Overall:
|
|
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
Target: |
Six months: 5.54 One year: 6.12 |
Support: |
Support1: 3.94 Support2: 3.27 |
Resistance: |
Resistance1: 4.74 Resistance2: 5.23 |
Pivot: |
4.61  |
Moving Average: |
MA(5): 4.44 MA(20): 4.61 
MA(100): 4.29 MA(250): 4.43  |
MACD: |
MACD(12,26): 0 Signal(9): 0  |
Stochastic oscillator: |
%K(14,3): 17.5 %D(3): 15.9  |
RSI: |
RSI(14): 47.5  |
52-week: |
High: 6.57 Low: 2.8 |
Average Vol(K): |
3-Month: 102 (K) 10-Days: 91 (K) |
|
Price, moving averages and Bollinger Bands |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CAPR ] has closed above bottom band by 22.2%. Bollinger Bands are 29.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
4.65 - 4.67 |
4.67 - 4.69 |
Low:
|
4.34 - 4.37 |
4.37 - 4.39 |
Close:
|
4.36 - 4.4 |
4.4 - 4.44 |
|
Company Description |
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California. |
Headline News |
Mon, 20 Mar 2023 Capricor Therapeutics Inc to Post FY2023 Earnings of ($1.41) Per ... - MarketBeat
Sat, 18 Mar 2023 Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2022 Earnings Call Transcript - Yahoo Finance
Wed, 15 Mar 2023 Capricor: Q4 Earnings Snapshot - The Washington Post
Wed, 15 Mar 2023 Capricor: Q4 Earnings Snapshot - Thehour.com
Wed, 08 Mar 2023 Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15 - Yahoo Finance
Thu, 02 Mar 2023 Capricor Therapeutics Receives Clinical Research Forum's - GlobeNewswire
|
Financial Analysis |
Price to Book Value: |
Neutral |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Price to Earnings: |
Neutral |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Discounted cash flow: |
Outperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Return on Assets: |
Outperform |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Return on Equity: |
Outperform |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Debt to Equity: |
Outperform |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: NASDAQ |
Sector: Healthcare |
Industry: Biotechnology |
Shares Out. |
0 (M) |
Shares Float |
25 (M) |
% Held by Insiders
|
2.453e+007 (%) |
% Held by Institutions
|
2.6 (%) |
Shares Short
|
328 (K) |
Shares Short P.Month
|
0 (K) |
Stock Financials |
EPS
|
-2.945e+007 |
EPS Est Next Qtl
|
-0.19 |
EPS Est This Year
|
-0.7 |
EPS Est Next Year
|
-0.76 |
Book Value (p.s.)
|
0 |
Profit Margin (%)
|
0 |
Operating Margin (%)
|
-1 |
Return on Assets (ttm)
|
163.9 |
Return on Equity (ttm)
|
0 |
Qtrly Rev. Growth
|
2.55e+006 |
Gross Profit (p.s.)
|
0 |
Sales Per Share
|
-30.33 |
EBITDA (p.s.)
|
-4.71149e+006 |
Qtrly Earnings Growth
|
-1.1 |
Operating Cash Flow
|
0 (M) |
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
PE Ratio
|
-0.01 |
PEG Ratio
|
0 |
Price to Book value
|
0 |
Price to Sales
|
-0.15 |
Price to Cash Flow
|
29.15 |
Stock Dividends |
Dividend
|
0 |
Forward Dividend
|
338220 |
Dividend Yield
|
0% |
Dividend Pay Date
|
2019-06-04 |
Ex-Dividend Date
|
Invalid DateTime. |
Your Ad Here
|
|